Medical Pulse (02192) announces 2023 results. Profit attributable to parent company owners was approximately RMB 242 million, up 106.5% year-on-year, with a final interest rate of 12.48 points per share

According to the Zhitong Finance App, Medicom (02192) announced its 2023 results, with revenue of about 412 million yuan, up 31.2% year on year; gross profit of about 251 million yuan, up 18.1% year on year; profit attributable to parent company owners was about 242 million yuan, up 106.5% year on year; adjusted net profit of about 271 million yuan, up 86.8% year on year; basic profit per share was 33.56 points, with a proposed final dividend of 12.48 points per share.

According to the announcement, most of the Group's revenue comes from precision marketing solutions, which provide digital medical marketing services for pharmaceutical and medical device companies. Benefiting from the return to normal hospital diagnosis and treatment after the epidemic and the acceleration of the approval process for new drugs, product sales and marketing work for pharmaceutical and medical equipment company customers resumed at an accelerated pace. The precise marketing and enterprise solutions provided by the group meet market needs, help customers achieve physician coverage throughout the life cycle of pharmaceutical products, and conduct physicians' academic education in a compliant, accurate and efficient manner, and have been widely recognized by customers of pharmaceutical and medical equipment companies. The number of customers covered by the solution was 182 throughout 2023, an increase of 40.0% from 130 in 2022. At the same time, the number of products covered increased steadily, from 284 in 2022 to 386 in 2023. The growing number of products has enabled the Group to further transform registered physician users on the platform into physicians participating in paid clicks. The number increased from 627,000 in 2022 to 774,000 in 2023, while the number of paid clicks also increased from 7.2 million in 2022 to 9.7 million. As a result, the Group's revenue from precision marketing and enterprise solutions for the year ended December 31, 2023 increased by 29.3% over the same period in 2022 to approximately $373 million.

The benefits of medical knowledge solutions mainly come from providing professional medical information covering continuing medical education and clinical decision support, including licensing the use of software for physicians, other registered users (including other medical professionals), and pharmaceutical companies. The revenue of medical knowledge solutions increased by about 31.6% year-on-year to 16.1 million yuan, mainly due to the Group providing more medical knowledge products and adding various membership marketing methods, which effectively increased the user unit price.

The revenue of the intelligent patient management solution increased by about 70.2% year-on-year to 23.2 million yuan, mainly due to the initial results and scale of the single-disease patient management platform established by the group. While academically educating doctors and improving the level of standardized diagnosis and treatment, it effectively links doctors and patients, and realizes patient management and education services scientifically and efficiently.